On GPCB’s most recent CC, they said the OS data would be mature in the “fall of 2007.” Now that the near-term reporting of the OS data has become an issue of consequence, the expected data maturity has been pushed back by about 9 months.
9 out of 10 biotechs make exactly this error - they project forward the event rate they see during active enrollment or shortly thereafter to predict when they will hit the event number. Yes, it is a credibility issue, but given that it encompasses 90% of biotechs it isn't a real separator.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.